Skip to content
MarketScale
‹ Back to Industries

Sciences

Japan’s Radioactive Water Release Won’t Impact Neighboring Countries, Despite China’s Opposition and Ban on Japanese Seafood

With news of China banning seafood from Japan, the debate around nuclear energy has always been fraught with concerns about safety, especially following high-profile incidents like Fukushima. However, it’s worth noting that nuclear plants across the world, including officials in countries vocally concerned about Japan’s handling of tritiated water, routinely have their own radioactive…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Alexandra Simon · ChinaFukushimaJapanRadioactive Release
Share

Key takeaways

01

With news of China banning seafood from Japan, the debate around nuclear energy has always been fraught with concerns about safety, especially following high-profile incidents like Fukushima.

02

However, it’s worth noting that nuclear plants across the world, including officials in countries vocally concerned about Japan’s handling of tritiated water, routinely have their own radioactive…

With news of China banning seafood from Japan, the debate around nuclear energy has always been fraught with concerns about safety, especially following high-profile incidents like Fukushima. However, it’s worth noting that nuclear plants across the world, including officials in countries vocally concerned about Japan’s handling of tritiated water, routinely have their own radioactive waste responsibilities. 

It’s easy to get caught in the emotion and politics of the situation, especially when it involves terms like “radioactive release,” but understanding the science and safety protocols is crucial. Independent organizations like the International Atomic Energy Agency (IAEA) provide not just oversight but also expertise in making sure that any release is carried out to stringent safety standards. For instance, the tritium levels being released from Fukushima meet standards set by the World Health Organization and the Japanese government. The release of tritiated water is a monitored, understood, and internationally sanctioned activity that comes as a part of the territory with nuclear energy. 

To further explain the safety of this effort and how public perception impacts nuclear outlook is Ken Petersen, President of the American Nuclear Society. He brings years of experience and knowledge on the subject. Previously he was the vice president for nuclear fuels at Exelon Generation Company (EGC) for more than 12 years. He even worked on a contract with the U.S. Department of Energy, and has a Bachelor’s and Master’s in nuclear engineering from the University of Wisconsin.

Petersen mentioned that Japan’s release of tritiated water — water that’s been heavily treated, undergoes safety protocols set by global standards. He further added that China’s opposition bears hypocrisy given that they, too, have also released radioactive water under those same guidelines.

Petersen’s Thoughts on Radioactive Water Release

“Sure. So, I mean, the site is no longer has room for expanded storage. So, something has to happen with the tritiated water. It’s been, you know, filtered twice and, you know, what is remaining is a little bit of tritium that’s going to be blended down even further and released. So, it’s going to be monitored and released. The IAEA has reviewed it. They will have somebody there monitoring it to assure that everything is done appropriately. So, this is no different than any other plant. 

“So, when you have a radioactive release, it is monitored and it meets the criteria. And it’s, you know, one-seventh of the World Health Organization levels. And it’s a fortieth of what the Japanese government limits are. So, it’s a very understood and very small amount. Well, there’s a history from their neighbors where, you know, some of their neighbors don’t get along very well. But the neighbors who are speaking loudly also have reactors where they’ll do the exact same thing. You know, they will have tritium releases. They will be monitored and be well within safety levels. Yeah, this shouldn’t impact that at all. So, this is a very unfortunate situation, you know, that the Fukushima plants had the earthquake and following tsunami. And it resulted with this large storage of tritiated water and it is just a monitored release. It should have no impact on the outlook for new nuclear.”

About the author

AS
Alexandra SimonFreelance Writer

Alexandra is a freelance writer based in New York City. She's a big fan of true crime television and the Oxford comma. She has a background in local news reporting, beat reporting, magazine writing, SEO writing, and copywriting.

New to MarketScale?

MarketScale is the platform Sciences companies use to turn their own experts into content like this. Want the short overview?

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Tekniplex Showcases Sustainable Materials Innovation at Paris Packaging Week 2026

Tekniplex Showcases Sustainable Materials Innovation at Paris Packaging Week 2026

At Paris Packaging Week 2026, Tekniplex showcased its latest sustainable materials innovations, emphasizing the intersection of materials science and brand storytelling. The company's booth featured a living wall and digital displays to engage a sustainability-conscious audience, highlighting advanced materials for sustainability and product performance in cosmetics packaging.

  • 01Tekniplex emphasized sustainable materials innovation at Paris Packaging Week 2026.
  • 02The company's booth featured eco-friendly design elements and immersive digital displays.
  • 03Tekniplex highlighted advancements in recyclable sealing systems and materials for cosmetics.

Apr 9, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

AS
Alexandra Simon

Freelance Writer

Alexandra is a freelance writer based in New York City. She's a big fan of true crime television and the Oxford comma. She has a background in local news reporting, beat reporting, magazine writing, SEO writing, and copywriting.